Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab.
Tonyali O, Coskun U, Yuksel S, Inanc M, Bal O, Akman T, Yazilitas D, Ulas A, Kucukoner M, Aksoy A, Demirci U, Uysal M, Tanriverdi O, Gunaydin Y, Sumbul AT, Yildiz R, Karaca H, Oksuzoglu B, Ciltas A, Buyukberber S, Benekli M; Anatolian Society of Medical Oncology (ASMO). Tonyali O, et al. Among authors: yildiz r. Breast. 2016 Feb;25:22-6. doi: 10.1016/j.breast.2015.11.006. Epub 2015 Dec 20. Breast. 2016. PMID: 26801412
Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer.
Tonyali O, Coskun U, Sener N, Inanc M, Akman T, Oksuzoglu B, Ozdemir NY, Yazilitas D, Benekli M, Uner A, Yamac D, Demirci U, Yildiz R, Karaca H, Unal OU, Bal O, Gumus M, Buyukberber S; Anatolian Society of Medical Oncology (ASMO). Tonyali O, et al. Among authors: yildiz r. J Cancer Res Clin Oncol. 2012 Dec;138(12):2145-51. doi: 10.1007/s00432-012-1296-x. Epub 2012 Aug 10. J Cancer Res Clin Oncol. 2012. PMID: 22878681
Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.
Kaplan MA, Isikdogan A, Koca D, Kucukoner M, Gumusay O, Yildiz R, Dayan A, Demir L, Geredeli C, Kocer M, Arslan UY, Inal A, Akman T, Coskun U, Sener N, Inanc M, Elkiran ET, Ozdemir NY, Durnalı AG, Suner A, Alici S, Tarhan MO, Boruban C, Oksuzoglu B, Urakci Z. Kaplan MA, et al. Among authors: yildiz r. Breast Cancer. 2014 Nov;21(6):677-83. doi: 10.1007/s12282-013-0441-y. Epub 2013 Jan 19. Breast Cancer. 2014. PMID: 23335064 Clinical Trial.
Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.
Tonyali O, Benekli M, Berk V, Coskun U, Ozkan M, Yildiz R, Ucgul E, Sevinc A, Uncu D, Demirci U, Buyukberber S; Anatolian Society of Medical Oncology (ASMO). Tonyali O, et al. Among authors: yildiz r. J Cancer Res Clin Oncol. 2013 Jun;139(6):981-6. doi: 10.1007/s00432-013-1409-1. Epub 2013 Mar 5. J Cancer Res Clin Oncol. 2013. PMID: 23463098 Clinical Trial.
Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab.
Tonyali O, Coskun U, Sener N, Inanc M, Akman T, Ulas A, Yazilitas D, Bal O, Kucukoner M, Yildirim Ozdemir N, Demirci U, Gunaydin Y, Yildiz R, Karaca H, Umit Unal O, Gumus M, Benekli M, Buyukberber S. Tonyali O, et al. Among authors: yildiz r. Onkologie. 2013;36(10):554-8. doi: 10.1159/000355156. Epub 2013 Sep 16. Onkologie. 2013. PMID: 24107908
191 results